سه شنبه 13 آذر 1403
[Archive]
دوره 31، شماره 147 - ( 5-1402 )
جلد 31 شماره 147 صفحات 322-316 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zakerkish M, Ghafuri Z, Kosarian Z, Hessam M, ShaterzadehYazdi M, Rafie S et al . Comparing the Efficacy of Duloxetine with High Tone Power Therapy in Diabetic Peripheral Neuropathic Pain: A Double-Blind Randomized Phase III Clinical Trial. J Adv Med Biomed Res 2023; 31 (147) :316-322
URL: http://journal.zums.ac.ir/article-1-6927-fa.html
URL: http://journal.zums.ac.ir/article-1-6927-fa.html
Comparing the Efficacy of Duloxetine with High Tone Power Therapy in Diabetic Peripheral Neuropathic Pain: A Double-Blind Randomized Phase III Clinical Trial. Journal of Advances in Medical and Biomedical Research. 1402; 31 (147) :316-322
چکیده: (1226 مشاهده)
Background and Objective: Diabetic neuropathy pain is a common pain condition that has a major negative impact on health-related quality of life. However, despite many studies, it remains difficult to treat neuropathic pain. This study aimed to compare the efficacy of duloxetine with high tone power therapy (HTPT) in diabetic peripheral neuropathic pain.
Materials and Methods: The study is a single-centre, phase III clinical trial comparing the effect of HTPT versus treatment with duloxetine in diagnosed diabetic neuropathy patients between October 2019 to December 2020. In the case group, the HTPT was used with a four-second duration for 30 minutes daily. This treatment was continued twice a week for 10 sessions. The control group received duloxetine (30 mg/m2 once a day). The treatment response was assessed based on the VAS score.
Results: The results showed that in both groups, there was a significant reduction in pain severity. In HTPT group, the average pain decreased from 7.36 to 4.6 and in duloxetine group from 7.7 to 4.8. During 8 measurements after the intervention; decrease in VAS score was higher in HTPT group (5.6) than in duloxetine group (6.5) in the first and fourth times after the intervention (P-Value=0.01). Further analysis demonstrated a positive correlation between pain severity and age so that, the pain also increases with advancing age.
Conclusion: The results of the present study showed that both duloxetine and high tone therapies are safe and effective methods for neuropathic pain relief.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Clinical medicine
دریافت: 1401/7/29 | پذیرش: 1401/11/2 | انتشار: 1402/7/5
دریافت: 1401/7/29 | پذیرش: 1401/11/2 | انتشار: 1402/7/5
فهرست منابع
1. Zakin E, Abrams R, Simpson DM. Diabetic Neuropathy. Semin Neurol. 2019;39(5):560-9. [DOI:10.1055/s-0039-1688978] [PMID]
2. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):CD007543. [DOI:10.1002/14651858.CD007543.pub2] [PMCID]
3. Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63(5):891-97. [DOI:10.1007/s00125-020-05085-9] [PMID] [PMCID]
4. Tesfaye S, Vileikyte L, Rayman G, et al. : Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629-38. [DOI:10.1002/dmrr.1225] [PMID]
5. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10(2):99-108.
6. Tracy JA, Dyck PJB. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19(1):1-26. [DOI:10.1016/j.pmr.2007.10.010] [PMID] [PMCID]
7. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458-86. [DOI:10.2337/diacare.27.6.1458] [PMID]
8. Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care. 2000;23(3):365-70. [DOI:10.2337/diacare.23.3.365] [PMID]
9. Jannu C, Puchchakayala G, Chandupatla VD, Suganthira Babu P. Efficacy of interferential therapy versus transcutaneous electrical nerve stimulation to reduce pain in patients with diabetic neuropathy diabetic neuropathy. Indian J Pub Health Res Develop.9(10):121-24 10. [DOI:10.5958/0976-5506.2018.01325.6]
10. Mekhail NA, Argoff CE, Taylor RS, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials. 2020;21(1):87. [DOI:10.1186/s13063-019-4007-y] [PMID] [PMCID]
11. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia. 2005;48(5):824-8. [DOI:10.1007/s00125-005-1728-0] [PMID]
12. Nesbit SA, Sharma R, Waldfogel JM, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2019;35(1):15-25. [DOI:10.1080/03007995.2018.1497958] [PMID]
13. Tawfik MK, Helmy SA, Badran DI, Zaitone SA. Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: Role of glia suppressing mechanisms. Life Sci. 2018;205:113-24. [DOI:10.1016/j.lfs.2018.05.025] [PMID]
14. Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the efficacy of duloxetine and pregabalin in pain relief associated with diabetic neuropathy. Cureus. 2019;11(7):e5293. [DOI:10.7759/cureus.5293]
15. Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy. Diabetes Care. 2011;34(4):818-22. [DOI:10.2337/dc10-1793] [PMID] [PMCID]
16. Yasuda H, Hotta N, Nakao K, Kasuga M, Kashiwagi A, Kawamori R. Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan. J Diabetes Investig. 2011;2(2):132-9. [DOI:10.1111/j.2040-1124.2010.00073.x] [PMID] [PMCID]
17. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-18. [DOI:10.1016/j.pain.2005.03.029] [PMID]
18. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411-20. [DOI:10.1212/01.wnl.0000240225.04000.1a] [PMID]
19. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. PAIN. 2013;154(12):2616-25. [DOI:10.1016/j.pain.2013.05.043] [PMID]
20. Reed MD, Van Nostran W. Assessing pain intensity with the visual analog scale: a plea for uniformity. J Clin Pharmacol. 2014;54(3):241-4. [DOI:10.1002/jcph.250] [PMID]
21. Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018 ;41(3):60-63. [DOI:10.18773/austprescr.2018.022] [PMID] [PMCID]
22. Cheraghian B, S Hashemi SJ, Hosseini SA,et al. Cohort profile: The Hoveyzeh Cohort Study (HCS): A prospective population-based study on non-communicable diseases in an Arab community of Southwest Iran. Med J Islam Repub Iran.2020. 34: 141. [DOI:10.47176/mjiri.34.141] [PMID] [PMCID]
23. Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede R-D. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm. 2020;127(4):589-624. [DOI:10.1007/s00702-020-02145-7] [PMID] [PMCID]
24. Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020;72(7):863-72. [DOI:10.1111/jphp.13241] [PMID]
25. Ko YC, Lee CH, Wu CS, Huang YJ. Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(11):e14576. [DOI:10.1111/ijcp.14576]
26. Shukla R, Khasbage S, Garg M, Singh S. Duloxetine-induced hypertensive urgency in type 2 diabetes mellitus with diabetic neuropathy. Indian J Pharmacol. 2020;52(3):213. [DOI:10.4103/ijp.IJP_370_19] [PMID] [PMCID]
27. Dingle A, Zeng W, Ness JP, et al. Strategies for interfacing with the trigeminal nerves in rodents for bioelectric medicine. J Neurosci Methods. 2019;324:108321. [DOI:10.1016/j.jneumeth.2019.108321] [PMID]
28. Vitale F, Litt B. Bioelectronics: the promise of leveraging the body's circuitry to treat disease. Bioelec Med. 2017 ;1(1):3-7. [DOI:10.2217/bem-2017-0010]
29. Raghav A, Singh P, Ahmad J. New insights into bioelectronic medicines: A new approach to tackle diabetic peripheral neuropathy pain in clinics. Diabetes Metab Syndr Clin Res Rev. 2019;13(2):1011-4. [DOI:10.1016/j.dsx.2019.01.021] [PMID]
30. Zakerkish M, Amiri F, Nasab NM, Ghorbani A.Comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: A double blind randomized controlled trial. Iran Red Crescent Med J. 2017;19(8):0. [DOI:10.5812/ircmj.59995]
31. Naderi Nabi B, Saberi A, Bakhshayesh Eghbali B, et al. Efficacy and safety of TENS and duloxetine in patients with painful diabetic neuropathy: A single blind randomized clinical trial. J Adv Med Biomed Res.2021;29(136) :286-92. [DOI:10.30699/jambs.29.136.286]
32. Khasbage S, Shukla R, Sharma P, Singh S. A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy. J Diabetes. 2021;13(7):532-41. [DOI:10.1111/1753-0407.13148] [PMID]
33. Alshimy AM, Shady NA, El Gohary AM, Turky KTY. Effect of high tone power therapy on neurophysiological measures and function outcome in patients with diabetic neuropathy. Eur J Mol Clin Med. 2020;7(9):269-75.
34. Schaffler-Schaden D, Sassmann R, Johansson T, et al. Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy. Medicine (Baltimore). 2020;99(19):e20149. [DOI:10.1097/MD.0000000000020149] [PMID] [PMCID]
35. Klassen A, Di Iorio B, Guastaferro P, Bahner U, Heidland A, De Santo N. High-tone external muscle stimulation in end-stage renal disease: Effects on symptomatic diabetic and uremic peripheral neuropathy. J Ren Nutr. 2008;18(1):46-51. [DOI:10.1053/j.jrn.2007.10.010] [PMID]
36. Weintraub MI, Cole SP. Pulsed magnetic field therapy in refractory neuropathic pain secondary to peripheral neuropathy: electrodiagnostic parameters--pilot study. Neurorehabil Neural Repair. 2004;18(1):42-6. [DOI:10.1177/0888439003261024] [PMID]
37. Zakerkish M, Raeisi D, Rafie S, et al. Comparison of efficacy of nortriptyline versus transcutaneous electrical nerve stimulation on painful peripheral neuropathy in patients with diabetes. Rom J Diabetes Nutr Metab Dis. 2019;26(4):401-11. [DOI:10.2478/rjdnmd-2019-0043]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
